Article Details

Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab as ...

Retrieved on: 2021-01-12 04:52:30

Tags for this article:

Click the tags to see associated articles and topics

Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab as .... View article details on hiswai:

Excerpt

The principal investigator of ORIENT-3, Professor Yuankai Shi, Associate Dean of Cancer Hospital, Chinese Academy of Medical Sciences, stated: ...

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo